{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:12:17Z","timestamp":1782400337680,"version":"3.54.5"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005062","name":"Fujirebio Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec040\">\n<jats:title>\nObjectives\n<\/jats:title>\n<jats:p>Primary aldosteronism (PA) diagnosis is a multistep process that begins with screening based on the plasma aldosterone-to-renin ratio (ARR). As cut-off values depend on the methods used, the aim of this study was 1) to validate the performances of new aldosterone and renin chemiluminescent immuno-assays using the Lumipulse<jats:sup>\u00ae<\/jats:sup> analyzer (Fujirebio<jats:sup>\u00ae<\/jats:sup>) and then 2) to define the criteria to distinguish PA patients from those with essential hypertension (EH).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec041\">\n<jats:title>\nMethods\n<\/jats:title>\n<jats:p>This monocentric retrospective study included 297 patients admitted to Georges Pompidou European Hospital, France, between January 2021 and December 2022 for the assessment of hypertension etiology. We evaluated analytical performances and compared Lumipulse<jats:sup>\u00ae<\/jats:sup> results for plasma renin (PRC) and plasma aldosterone (PAC) concentrations (n\u2009=\u2009196) as well as 24-hour urine aldosterone excretion (24UA) (n\u2009=\u2009201) to the reference methods (PRC: Liaison XL<jats:sup>\u00ae<\/jats:sup> Diasorin<jats:sup>\u00ae<\/jats:sup>; PAC and 24UA: LC-MS\/MS). Receiver operating characteristic curve analysis was used to define the cut-off values for ARR, PAC, and 24UA to distinguish between PA and EH patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec042\">\n<jats:title>\nResults\n<\/jats:title>\n<jats:p>Analytical characteristics were in accordance with requested performances. Our results showed excellent correlations between Lumipulse<jats:sup>\u00ae<\/jats:sup> and our reference methods. We propose cut-off values of 35 pmol\/mIU as the ARR, 260 pmol\/L for PAC, and 49 nmol\/24h for 24UA for predicting PA diagnosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec043\">\n<jats:title>\nConclusions\n<\/jats:title>\n<jats:p>Lumipulse<jats:sup>\u00ae<\/jats:sup> (Fujirebio<jats:sup>\u00ae<\/jats:sup>) is a reliable alternative for measuring PRC, PAC, and 24UA for predicting PA diagnosis with the use of corresponding cut-off values for each criterion.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0319219","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T18:50:22Z","timestamp":1740509422000},"page":"e0319219","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measurement accuracy and cutoffs for predicting primary aldosteronism diagnosis using Lumipulse\u00ae for renin and aldosterone measurements"],"prefix":"10.1371","volume":"20","author":[{"given":"Maude","family":"Laney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appoline","family":"Nabi-Bourgois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-1780","authenticated-orcid":true,"given":"Julien","family":"Mallart-Riancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Chebbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-6968","authenticated-orcid":true,"given":"Stephanie","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"12","key":"pone.0319219.ref001","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)","volume":"41","author":"G Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"8","key":"pone.0319219.ref002","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"P Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0319219.ref003","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"S Savard","year":"2013","journal-title":"Hypertension"},{"issue":"12","key":"pone.0319219.ref004","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"P Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"pone.0319219.ref005","doi-asserted-by":"crossref","first-page":"e0272049","DOI":"10.1371\/journal.pone.0272049","article-title":"Clinical and biochemical predictors and predictive model of primary aldosteronism","volume":"17","author":"W Manosroi","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"pone.0319219.ref006","doi-asserted-by":"crossref","first-page":"e0277902","DOI":"10.1371\/journal.pone.0277902","article-title":"Illness perspectives in patients with primary aldosteronism","volume":"17","author":"O Ragnarsson","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"pone.0319219.ref007","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"JW Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0319219.ref008","doi-asserted-by":"crossref","first-page":"e0267732","DOI":"10.1371\/journal.pone.0267732","article-title":"Characteristics of aldosterone-producing adenomas in patients without plasma renin activity suppression","volume":"17","author":"H Kubo","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"pone.0319219.ref009","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/HJH.0000000000001735","article-title":"Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration","volume":"36","author":"S Baron","year":"2018","journal-title":"J Hypertens"},{"issue":"1","key":"pone.0319219.ref010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-16-0003","article-title":"A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism","volume":"175","author":"V Tsiavos","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"pone.0319219.ref011","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1515\/cclm-2015-1094","article-title":"Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension","volume":"54","author":"GP Rossi","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"pone.0319219.ref012","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1055\/s-0034-1374638","article-title":"The role of urinary aldosterone for the diagnosis of primary aldosteronism","volume":"46","author":"J Ceral","year":"2014","journal-title":"Horm Metab Res"},{"issue":"3","key":"pone.0319219.ref013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ando.2016.05.001","article-title":"SFE\/SFHTA\/AFCE primary aldosteronism consensus: introduction and handbook","volume":"77","author":"L Amar","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"issue":"11","key":"pone.0319219.ref014","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1515\/cclm-2022-0576","article-title":"Analytical evaluation and bioclinical validation of new aldosterone and renin immunoassays","volume":"60","author":"C Coulon","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"pone.0319219.ref015","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1515\/cclm-2021-0102","article-title":"Validation of the Fujirebio Lumipulse G1200 aldosterone assay for measurements during adrenal venous sampling for primary hyperaldosteronism","volume":"59","author":"FC Vermue","year":"2021","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"pone.0319219.ref016","doi-asserted-by":"crossref","first-page":"bvae080","DOI":"10.1210\/jendso\/bvae080","article-title":"Screening cutoff values for the detection of aldosterone-producing adenoma by LC-MS\/MS and a novel noncompetitive CLEIA","volume":"8","author":"Y Ono","year":"2024","journal-title":"J Endocr Soc"},{"issue":"5","key":"pone.0319219.ref017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1507\/endocrj.EJ23-0695","article-title":"Adrenal venous sampling criteria for chemiluminescent enzyme immunoassay as a preferable alternative to radioimmunoassay in primary aldosteronism","volume":"71","author":"K Nakai","year":"2024","journal-title":"Endocr J"},{"issue":"1","key":"pone.0319219.ref018","doi-asserted-by":"crossref","first-page":"26040","DOI":"10.1038\/s41598-024-75645-1","article-title":"Comparative analysis of aldosterone and renin assays for primary aldosteronism screening","volume":"14","author":"Y Taki","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0319219.ref019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00004872-200018040-00006","article-title":"Comparison of nurse- and physician-determined clinic blood pressure levels in patients referred to a hypertension clinic: implications for subsequent management","volume":"18","author":"A La Batide-Alanore","year":"2000","journal-title":"J Hypertens"},{"issue":"12","key":"pone.0319219.ref020","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)","volume":"41","author":"G Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"6","key":"pone.0319219.ref021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0034-1367033","article-title":"Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading","volume":"46","author":"S Pilz","year":"2014","journal-title":"Horm Metab Res"},{"issue":"7","key":"pone.0319219.ref022","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/1354750X.2011.614015","article-title":"Two-site automated chemiluminescent assay for measurement of immunoreactive renin","volume":"16","author":"D Gruson","year":"2011","journal-title":"Biomarkers"},{"issue":"6","key":"pone.0319219.ref023","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/HJH.0b013e32833857ad","article-title":"A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin","volume":"28","author":"A Morganti","year":"2010","journal-title":"J Hypertens"},{"issue":"10","key":"pone.0319219.ref024","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1210\/jc.2012-1917","article-title":"A clinical prediction score to diagnose unilateral primary aldosteronism","volume":"97","author":"EM K\u00fcpers","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0319219.ref025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/HJH.0b013e3282f61f8c","article-title":"Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism","volume":"26","author":"G Bernini","year":"2008","journal-title":"J Hypertens"},{"issue":"11","key":"pone.0319219.ref026","doi-asserted-by":"crossref","first-page":"e111949","DOI":"10.1371\/journal.pone.0111949","article-title":"Decrease in urinary creatinine excretion in early stage chronic kidney disease","volume":"9","author":"E Tynkevich","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"pone.0319219.ref027","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"TA Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0319219.ref028","article-title":"NCCLS C. CLSI EP15-A3:","volume-title":"User Verification of Performance for Precision and Trueness","year":"2014"},{"issue":"1","key":"pone.0319219.ref029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1210\/jc.2004-1149","article-title":"The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling","volume":"90","author":"S-C Tiu","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"pone.0319219.ref030","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/jc.2002-021476","article-title":"Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism","volume":"88","author":"A Tanabe","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"pone.0319219.ref031","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. results in hypertensive patients","volume":"141","author":"K Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"issue":"1","key":"pone.0319219.ref032","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"JM Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0319219.ref033","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41371-020-00465-5","article-title":"Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism","volume":"36","author":"K Teruyama","year":"2022","journal-title":"J Hum Hypertens"},{"key":"pone.0319219.ref034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jchromb.2012.11.013","article-title":"Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry","author":"E Hinchliffe","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"12","key":"pone.0319219.ref035","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1097\/HJH.0000000000000727","article-title":"Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays","volume":"33","author":"J Manolopoulou","year":"2015","journal-title":"J Hypertens"},{"issue":"4","key":"pone.0319219.ref036","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014)","volume":"37","author":"K Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"issue":"9","key":"pone.0319219.ref037","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009","volume":"58","author":"T Nishikawa","year":"2011","journal-title":"Endocr J"},{"issue":"7","key":"pone.0319219.ref038","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0895-7061(03)00858-6","article-title":"Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study","volume":"16","author":"S Abdelhamid","year":"2003","journal-title":"Am J Hypertens"},{"issue":"8","key":"pone.0319219.ref039","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1515\/cclm-2016-0841","article-title":"Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS\/MS","volume":"55","author":"DC Lin","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"Supplement_1","key":"pone.0319219.ref040","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-SAT-012","article-title":"SAT-012 Urinary aldosterone assay using LC-MS\/MS could improve primary aldosteronism screening","volume":"3","author":"S Travers","year":"2019","journal-title":"J Endocr Soc"},{"key":"pone.0319219.ref041","article-title":"LC-MS\/MS measurement for urinary aldosterone improves primary aldosteronism screening","author":"S Travers","year":"2019","journal-title":"Endocr Abstr"},{"key":"pone.0319219.ref042","doi-asserted-by":"crossref","first-page":"859347","DOI":"10.3389\/fendo.2022.859347","article-title":"Re-assessment of the oral salt loading test using a new chemiluminescent enzyme immunoassay based on a two-step sandwich method to measure 24-hour urine aldosterone excretion","volume":"13","author":"Y Ozeki","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"pone.0319219.ref043","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.4155\/bio-2016-0115","article-title":"Determination of urinary aldosterone using a plasma aldosterone 2D ID LC-MS\/MS method","volume":"8","author":"Y Bekkach","year":"2016","journal-title":"Bioanalysis"},{"issue":"8","key":"pone.0319219.ref044","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/clinchem\/hvad065","article-title":"A novel enzymatic hydrolysis method for urine aldosterone quantification: a case for reassessing clinical cut-offs of primary aldosteronism","volume":"69","author":"M Yazdanpanah","year":"2023","journal-title":"Clin Chem"},{"key":"pone.0319219.ref045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2019.03.012","article-title":"Establishment of a rapid and simple liquid chromatography tandem mass spectrometry method for measuring aldosterone in urine","author":"Y Yin","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"9","key":"pone.0319219.ref046","doi-asserted-by":"crossref","first-page":"bvaa100","DOI":"10.1210\/jendso\/bvaa100","article-title":"Reassessment of urinary aldosterone measurement after saline infusion in primary aldosteronism","volume":"4","author":"H Kaneko","year":"2020","journal-title":"J Endocr Soc"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T18:50:46Z","timestamp":1740509446000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319219"}},"subtitle":[],"editor":[{"given":"Etsuro","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319219","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}